生技學名藥市場：與規範相關的問題點

本報告已在2011年12月21日停止出版。

簡介

目錄

Abstract

Introduction

The sales that biologic agents command and the costs that they impose for payers combine to generate intense interest in the development of generic biologic agents, or biogenerics. However, the biogenerics market has been very slow to establish itself. The key reason is the lack of a defined regulatory framework and uncertainty-on the part of manufacturers and regulators alike-regarding what biogenerics will look like and how they will reach the market.

Get the Answers You Need to Shape Your Strategy

In the spring of 2006, two companies made history by producing the fi rst two approved biogenerics in the European Union. Which two companies were they, and what products were approved? What steps has the European Medicines Agency (EMEA) taken to clarify the path to approval? The biologics that bring in the most sales will be the natural focus of biogeneric development. Which branded biologics are the most popular targets? In late September 2006, Representative Henry Waxman introduced the Access to Life-Saving Medicine Act, which would amend section 351 of the Public Health Service Act. How could this bill foster the development of biogeneric products in the United States? What other actions are interested parties taking? Several generic drug manufacturers have entered or are hoping to enter the biogenerics market. Which companies are they and which biological products are they targeting? What business models are they using?

Scope

• The biologics market: origins and progress.
• The regulatory pathway for biologics: United States and Europe.
• The biogenerics market: origins and progress.
• Current and potential regulatory pathways for biogenerics: United States and Europe.
• Select company profi les: biopharmaceutical companies and biogenerics companies.

Mentioned in This Spectrum Report

Biologic brands

• Aranesp
• Avastin
• Enbrel
• Epogen
• Herceptin
• Humulin
• Intron A
• MabThera
• Neopogen
• Neulasta
• Procrit
• Protropin
• Pulmozyme
• Recombivax
• Remicade
• Rituxan
• Roferon-A

Companies

• Amgen
• Barr Pharmaceuticals
• Berlex
• Biogen Idec
• BiogeneriX
• BioPartners
• Cangene
• Celgene
• Celltech
• Centocor
• Dr. Reddy' s Laboratories
• Dragon Pharmaceuticals
• Eli Lilly
• GeneMedix
• Genentech
• Genzyme
• Johnson & Johnson
• LG Life Sciences
• MedImmune
• Merck
• Momenta Pharmaceuticals
• Ortho Biotech
• Phage Biotechnology
• Pliva
• Prolong Pharmaceuticals
• Ratiopharm
• Roche
• Sandoz
• Schering-Plough
• ScinoPharm Biotech
• Serono
• Shantha Biotech
• Stada Biogenerics
• Takeda
• Tanabe-Seiyaku
• Teva Pharmaceuticals
• Wockhardt
• Wyeth

Table of Contents

• Executive Summary
• Strategic Considerations
• Stakeholder Implications
• Introduction
• Biologics Market: Background and Status
• Origins and Progress of the Industry
• Key Biologic Brands
• Existing Regulatory Pathways for Biologics
• U.S. Biologic Regulation: An Evolving and Complicated History
• European Biologic Regulation: the EMEA' s Centralized Procedure
• Stumbling Blocks for Biogenerics
• Biologics: Is the Process the Product?
• For Some Products, U.S. Generics Manufacturers Point to 505(b)(2)
• For BLA-Regulated Products, Nowhere to Start
• Biogenerics Finally Crash the Party
• The EMEA Gives the Green Light to the First Biogenerics
• Omnitrope Fights Its Way to the U.S. Market
• Proactive Legislation in the United States and Europe
• United States-At Least a Beginning
• Implications of Omnitrope' s Approval
• Access to Life-Saving Medicine Act
• Europe-A More Concrete Approach
• Remaining Challenges
• A Look at Select Commercial Contenders
• Biologics Companies
• Biogenerics Companies
• Sandoz
• Teva Pharmaceuticals
• Pliva (Barr Pharmaceuticals)
• Dr. Reddy' s Labs
• Wockhardt
• BiogeneriX (Ratiopharm)
• Stada Biogenerics
• BioPartners
• Cangene
• Dragon Pharmaceuticals
• GeneMedix
• Momenta Pharmaceuticals
• Phage Biotechnology
• Prolong Pharmaceuticals
• ScinoPharm Biotech
• Shantha Biotech

Tables

• 1. Patent and Exclusivity Expiries of Key Biologics
• 2. EMEA' s Adopted Biosimilar Guidelines as of November 2006
• 3. EMEA' s Working Concept Papers for Biogenerics Approvals as of November 2006
• 4. Key Challenges for Biogenerics Manufacturers

Figures

• 1. U.S. Biotech Industry Sales Growth, 1994-2004
• 2. Timeline of Biogenerics Commercialization Milestones
• 3. Top Biotech Companies: Annual Company-Reported Net Sates Revenues, 2000-2005
• 4. Business Strategies for Tapping the Biologics Market with Biogenerics

相關商品

生技仿製藥相關市場調查報告書

歐洲的生物後續品市場的分析

Analysis of European Biosimilars Market

價格 : US $ 6500

出版日期 : 2011年12月

歐洲生物仿製藥：技術創新為威脅或是機會

Biosimilar Drugs in Europe: threat or opportunity to innovation?

價格 : US $ 595

出版日期 : 2011年11月

加拿大:學名藥和生技仿製藥概要

Canada: Generics and Biosimilars Overview

價格 : US $ 1900

出版日期 : 2011年11月

Decision Resources, Inc.發行的製藥相關市場調查報告書

傳染病疫苗開發平台:競爭檢討

Special Report: The Infectious Disease Vaccine Pipeline--A Competitive Review

價格 : US $ 9200

出版日期 : 2011年06月

感染疾病疫苗:未滿足需求和對醫藥品產業來說的機會

Special Report: Infectious Disease Vaccines--Unmet Needs and Opportunities for Pharma

價格 : US $ 9200

出版日期 : 2011年06月

自閉症譜系障礙:高未滿足需求創造出很大的市場機會

Special Report: Autism Spectrum Disorders--High Unmet Needs Create Significant Market Opportunities

價格 : US $ 9200

出版日期 : 2011年06月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!